Certara (NASDAQ:CERT) Given New $8.00 Price Target at Barclays

Certara (NASDAQ:CERT) had its price target reduced by Barclays from $13.00 to $8.00 in a research report released on Friday morning,Benzinga reports. They currently have an overweight rating on the stock.

Several other equities research analysts have also weighed in on CERT. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Certara in a report on Monday, December 29th. Stephens decreased their price objective on shares of Certara from $15.00 to $12.00 and set an “overweight” rating on the stock in a research note on Friday, December 12th. KeyCorp dropped their price objective on shares of Certara from $13.00 to $12.00 and set an “overweight” rating for the company in a report on Thursday, January 8th. Rothschild & Co Redburn set a $10.00 target price on Certara in a report on Friday, November 21st. Finally, BMO Capital Markets began coverage on Certara in a research report on Thursday, November 13th. They set a “market perform” rating and a $9.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $11.10.

Certara Price Performance

Shares of CERT traded up $0.28 during mid-day trading on Friday, reaching $7.08. The company had a trading volume of 4,625,594 shares, compared to its average volume of 3,074,283. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.09 and a quick ratio of 2.09. The company has a market capitalization of $1.13 billion, a P/E ratio of -708.00 and a beta of 1.47. Certara has a twelve month low of $6.04 and a twelve month high of $15.38. The company’s 50-day moving average is $8.36 and its 200-day moving average is $9.89.

Certara (NASDAQ:CERT) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). Certara had a negative net margin of 0.38% and a positive return on equity of 4.19%. The company had revenue of $103.65 million during the quarter, compared to the consensus estimate of $103.23 million. During the same quarter last year, the company earned $0.15 earnings per share. The business’s revenue was up 3.2% on a year-over-year basis. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. On average, equities analysts anticipate that Certara will post 0.28 EPS for the current year.

Institutional Investors Weigh In On Certara

A number of institutional investors and hedge funds have recently made changes to their positions in CERT. Northwestern Mutual Wealth Management Co. boosted its holdings in Certara by 2,733.3% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock valued at $26,000 after acquiring an additional 2,870 shares during the last quarter. First Horizon Corp acquired a new position in Certara during the 3rd quarter valued at about $30,000. Versant Capital Management Inc boosted its stake in shares of Certara by 66.7% in the 3rd quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock valued at $35,000 after purchasing an additional 1,153 shares during the last quarter. Osaic Holdings Inc. grew its position in shares of Certara by 50.7% during the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock worth $41,000 after buying an additional 1,175 shares during the period. Finally, Elevation Point Wealth Partners LLC bought a new stake in shares of Certara during the second quarter worth approximately $59,000. Institutional investors own 73.96% of the company’s stock.

Key Certara News

Here are the key news stories impacting Certara this week:

• Positive Sentiment: FY‑2025 results showed 9% revenue growth to $418.8M, adjusted EBITDA up 10% to $134.5M, and Q4 software revenue +10% — evidence of recovering commercial momentum in the higher‑margin software business. Certara Reports Fourth Quarter 2025 Financial Results
• Positive Sentiment: New CEO Jon Resnick is executing an operational overhaul with plans for sharper strategic focus and ~ $10M of cost avoidance — a management change investors often view as constructive for execution and long‑term growth. CEO signals operational overhaul
• Positive Sentiment: Barclays maintained an Overweight stance on CERT (despite lowering its price target), indicating some sell‑side support for the name even after recent guidance/earnings. Barclays price target change
• Neutral Sentiment: Management will participate in upcoming investor conferences — a chance to press the case for the turnaround and provide more color to investors. Investor conference participation
• Neutral Sentiment: Broker and media earnings breakdowns are circulating (useful for detail on items behind adjusted metrics and bookings vs. revenue). Earnings breakdown
• Negative Sentiment: GAAP and adjusted metrics disappointed in places: Q4 adjusted diluted EPS of $0.09 (down vs. prior year) and a GAAP net loss; management guided FY‑2026 revenue of only 0–4% (and set revenue range below Street expectations), which pressured near‑term growth expectations. Guidance and Q4 results
• Negative Sentiment: Craig Hallum downgraded CERT from Buy to Hold, reflecting analyst caution after the quarter and guidance; such downgrades can increase selling pressure. Analyst downgrade (Craig Hallum)

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.